Corrigendum to “Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret”

Neuropharmacology 40 (2001) 465 www.elsevier.com/locate/neuropharm

Corrigendum

Corrigendum to “Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret” [Neuropharmacology 38 (1999) 289–297]夽 A. Robichaud a

a,*

, F.D. Tattersall b, I. Choudhury b, I.W. Rodger

a

Merck Frosst Canada Incorporated, Centre for Therapeutic Research, P.O. Box 1005, Pointe-Claire-Dorval, Qc, H9R 4P8, Canada b Merck Sharp and Dohme, Neuroscience Research Centre, Terlings Park, Harlow, Essex, CM20 2QR, UK

It recently came to our attention that a mistake occurred in an article we published in Neuropharmacology in 1999 (Robichaud et al., 1999, Emesis induced by type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret. Neuropharmacology 38: 289-297). In that paper the following structure (upper panel, Figure 1) was incorrectly named RS14203. It should be referred to as 6-(4-pyridylmethyl)-8-(3-nitrophenyl)quinoline or PMNPQ in its abbreviated form, as indicated below:

6-(4-pyridylmethyl)-8-(3-nitrophenyl)quinoline (or PMNPQ) We sincerely apologise for this mistake.

夽

PII of original article S0028-3908(98)00190-7. * Corresponding author.

0028-3908/01/$ - see front matter  2001 Elsevier Science Ltd. All rights reserved. PII: S 0 0 2 8 - 3 9 0 8 ( 0 0 ) 0 0 2 1 2 - 4